Actively Recruiting
Evaluating Rezpegaldesleukin Injections Compared to Placebo for Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 and Older
Led by Nektar Therapeutics · Updated on 2026-10-21
510
Participants Needed
20
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Rezpegaldesleukin as a treatment for people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its effect on this skin condition. The overall participation lasts about 15 months. Participants will receive Rezpegaldesleukin or placebo injections during an induction period every 2 weeks. Afterward, during the maintenance period, Rezpegaldesleukin is given every 4 or 12 weeks, while placebo is given every 4 weeks. There is also an open-label escape phase where dosing frequency is decided by the investigator. Treatments are given by subcutaneous injection. During the study, participants will undergo assessments including the Investigators Global Assessment IGA score, Eczema Area and Severity Index EASI, itch and skin pain scales, sleep quality questionnaires, and asthma and nasal symptom scores. These evaluations happen at baseline, Week 6, and Week 24. Safety is monitored throughout, with adverse events recorded until about Week 56. Participants are followed for approximately 15 months in total.
CONDITIONS
Brief Title
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Research Team
N
Nektar Recruitment
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here